Neurofibromatosis type 1 (NF1) is a genetic condition that causes changes in skin pigment and the growth of mostly benign tumors along nerves, and it can affect your skin, bones, eyes, and nervous system. Knowing What Is NF1 Neurofibromatosis, this helps you recognize why symptoms vary so much between people and why lifelong, specialized care matters.
You’ll learn how NF1 develops, what signs to watch for, and how clinicians diagnose the condition so you can take informed steps if NF1 might affect you or someone close to you. The article will also explain treatment options and when to seek coordinated care from specialists.
Understanding NF1 Neurofibromatosis
NF1 primarily affects the skin, nerves, and bones. It often appears in childhood with visible skin changes and can cause nerve-related tumours and learning or vision issues.
Definition and Overview
Neurofibromatosis type 1 (NF1) is a genetic disorder that causes benign tumors called neurofibromas to grow on or under your skin and along peripheral nerves. You may notice flat, light brown café-au-lait spots at birth or in early childhood and small freckling in the armpits or groin by school age. Tumors range from tiny, subcutaneous nodules to larger plexiform neurofibromas that can cause disfigurement or compress nearby structures.
NF1 can involve the brain, spinal cord, and bones, producing scoliosis, tibial bowing, or bone dysplasia. Disease severity varies widely even within the same family, so clinical monitoring is important.
Key Symptoms and Signs
Look for multiple café-au-lait macules (six or more) measuring over 5 mm in young children or >15 mm in adults; these are a common early sign. Freckling in skin folds, Lisch nodules in the iris, and multiple cutaneous neurofibromas usually appear over time and help confirm diagnosis.
Watch for plexiform neurofibromas that feel like soft, baggy lumps and may cause pain, numbness, or functional problems. Other issues include learning disabilities, ADHD, headaches, optic pathway gliomas that can reduce vision, and skeletal abnormalities such as scoliosis. Tumor malignant transformation is uncommon but possible; report rapid growth, new pain, or neurological changes immediately.
Genetic Causes and Risk Factors
NF1 results from pathogenic variants in the NF1 gene on chromosome 17, which encodes neurofibromin, a protein that helps regulate cell growth. Loss or dysfunction of neurofibromin increases RAS pathway signaling, promoting tumor formation.
You inherit NF1 in an autosomal dominant pattern: a single altered copy of NF1 can cause the disorder. About half of cases arise from a new (de novo) NF1 mutation, so you may have no family history. Penetrance is high by adulthood, meaning most people with an NF1 variant will show signs, but expressivity is variable — severity and specific symptoms differ widely between individuals.
Diagnosis and Treatment of NF1 Neurofibromatosis
Diagnosis relies on specific physical signs and family history; treatment focuses on monitoring, symptom-directed surgeries or medications, and coordinated care among specialists.
Medical Diagnostic Criteria
Your clinician will use established clinical criteria to diagnose NF1, not a single lab test. Major signs include six or more café-au-lait spots (≥5 mm in children, ≥15 mm in adults), two or more neurofibromas or one plexiform neurofibroma, axillary/inguinal freckling, optic pathway glioma, two or more Lisch nodules (iris hamartomas), distinctive bony lesions (sphenoid dysplasia or tibial pseudarthrosis), or a first‑degree relative with NF1.
Genetic testing for NF1 gene mutations can confirm diagnosis when clinical signs are ambiguous or for family planning. You may receive baseline assessments: skin exam, ophthalmology, blood pressure, developmental and learning evaluations, and imaging (MRI) when tumors or neurologic symptoms are suspected.
Treatment Options and Management
You will likely follow a surveillance-driven plan with interventions as needed rather than a single cure. Routine monitoring includes annual skin and neurologic exams, blood pressure checks, and periodic eye exams in children. MRI scans target symptomatic or suspected internal tumors.
Interventions include:
- Surgery for disfiguring or compressive neurofibromas and for certain bone lesions.
- Selumetinib (a MEK inhibitor) for symptomatic, inoperable plexiform neurofibromas in children and some adults.
- Pain management, physiotherapy, and specialized educational support for learning differences.
- Targeted oncology treatments (chemotherapy, radiotherapy) reserved for malignant peripheral nerve sheath tumors or other cancers.
Multidisciplinary care teams (genetics, neurosurgery, dermatology, orthopedics, oncology, ophthalmology) coordinate individualized plans. You should maintain records of lesion changes and report new neurologic symptoms promptly.
Long-Term Outlook and Complications
Your prognosis varies widely; many people have mild disease while others face progressive complications. Common long-term issues include growth of cutaneous and plexiform neurofibromas, learning disabilities, hypertension, scoliosis, and risk (5–15% lifetime) of malignant peripheral nerve sheath tumors in those with plexiform lesions.
Lifelong surveillance reduces morbidity by detecting treatable complications early. Reproductive counseling and prenatal or preimplantation genetic testing can inform family planning. Prompt management of complications—surgical correction of bone deformities, targeted drug therapy for tumor control, and supportive services for cognitive or psychosocial needs—improves quality of life.